Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
11 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 44(2); June 2012
Prev issue Next issue
Editorial
New Step of Joint Publication with the Korean Association for Clinical Oncology
Il Han Kim
Cancer Res Treat. 2012;44(2):73-73.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.73
AbstractAbstract PDFPubReaderePub
No abstract available.
  • 9,994 View
  • 35 Download
Close layer
Review Articles
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
D. Nathan Kim, Taek-Keun Nam, Kevin S. Choe, Hak Choy
Cancer Res Treat. 2012;44(2):74-84.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.74
AbstractAbstract PDFPubReaderePub
Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the potential molecular targets/agents for treatment of this disease will be reviewed. Understanding these issues will aid in the development of rationally designed clinical trials, so as to determine best means of appropriately incorporating these molecular strategies, to the current standard of radiation and chemotherapy regimens, for the treatment of locally advanced NSCLC.

Citations

Citations to this article as recorded by  
  • The Correlation between Hemostatic Parameters and Mortality Rate in Patients with Non-Small Cell Lung Cancer
    Noni Novisari Soeroso, Fannie Rizki Ananda, Ganda Samosir, Herman Hariman, Putri Chairani Eyanoer
    Hematology Reports.2021; 13(3): 8361.     CrossRef
  • Radiation Therapy as a Backbone of Treatment of Locally Advanced Non-Small Cell Lung Cancer
    Aaron M. Laine, Kenneth D. Westover, Hak Choy
    Seminars in Oncology.2014; 41(1): 57.     CrossRef
  • Recurrence and Survival Outcomes After Anatomic Segmentectomy Versus Lobectomy for Clinical Stage I Non–Small-Cell Lung Cancer: A Propensity-Matched Analysis
    Rodney J. Landreneau, Daniel P. Normolle, Neil A. Christie, Omar Awais, Joseph J. Wizorek, Ghulam Abbas, Arjun Pennathur, Manisha Shende, Benny Weksler, James D. Luketich, Matthew J. Schuchert
    Journal of Clinical Oncology.2014; 32(23): 2449.     CrossRef
  • High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas
    Ping‐Li Sun, Yan Jin, Hyojin Kim, Choon‐Taek Lee, Sanghoon Jheon, Jin‐Haeng Chung
    Cancer Cytopathology.2013; 121(6): 311.     CrossRef
  • Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
    Gangjun Du, Yingming Yang, Yaping Zhang, Ting Sun, Weijie Liu, Yingying Wang, Jiahuan Li, Houyun Zhang
    Cancer Chemotherapy and Pharmacology.2013; 71(4): 893.     CrossRef
  • 14,513 View
  • 72 Download
  • 5 Crossref
Close layer
Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
Yoon-Koo Kang, Hye Jin Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
Cancer Res Treat. 2012;44(2):85-96.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.85
AbstractAbstract PDFPubReaderePub
Despite their rarity in incidence and prevalence, gastrointestinal stromal tumors (GISTs) have emerged as a distinct and noteworthy pathogenetic entity. The clinical management of GISTs has rapidly evolved due to the recent elucidation of their oncogenic signal transduction pathway and the introduction of molecular-targeted therapies. Successful management of GISTs requires a multidisciplinary approach firmly based on an accurate histopathologic diagnosis. In 2007, the Korean GIST study group published the first guideline for optimal diagnosis and treatment of GISTs in Korea. The second version of the guideline was published in 2010. Herein, we provide the results of relevant clinical studies for the purpose of further revision to the guideline. We expect this new guideline will enhance the accuracy of diagnosis, as performed by members of the Korean associate of physicians involved in GIST patient care, thus improving the efficacy of treatment.

Citations

Citations to this article as recorded by  
  • Diagnostic and Therapeutic Challenges in the Management of Acute Massive Overt Bleeding of Jejunal Gastrointestinal Stromal Tumours: Case Series
    Satish Subbiah Nagaraj, Sriram Deivasigamani, Amresh Aruni, Hemanth Kumar, Anurag Sachan, Jayanta Samanta, Amanjit Bal
    Journal of Gastrointestinal Cancer.2023; 54(1): 316.     CrossRef
  • The Feasibility and Safety of the Clip-and-Snare Method with a Prelooping Technique for Gastric Submucosal Tumors Removal: A Single-Center Experience (with Video)
    Qi Tang, Rui-Yue Shi, Jun Yao, Li-Sheng Wang, De-Feng Li, Alessandro Granito
    Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1.     CrossRef
  • Gastrointestinal stromal tumor of the small intestine of high malignant potential
    Aleksandar Mladenović, Miljan Jovančević, Zoran Milošević
    PONS - medicinski casopis.2022; 19(1): 33.     CrossRef
  • Rare Occurrence of Microsatellite Instability in Gastrointestinal Stromal Tumors
    Joonhong Park, Hae Jung Sul, Jeong Goo Kim
    Medicina.2021; 57(2): 174.     CrossRef
  • The Pathologic Confirmation in Subepithelial Tumors
    Kwan Hong Lee, Chan Kyoo Yoo, Hang Lak Lee, Kang Nyeong Lee, Dae Won Jun, Oh Young Lee, Dong Soo Han, Byung Chul Yoon, Ho Soon Choi, Jai Hoon Yoon
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(3): 215.     CrossRef
  • Diagnosis and Treatment of Duodenal Gastrointestinal Stromal Tumors
    Haojie Du, Longgui Ning, Sha Li, Xinhe Lou, Hongtan Chen, Fengling Hu, Guodong Shan, Fenming Zhang, Guoqiang Xu
    Clinical and Translational Gastroenterology.2020; 11(3): e00156.     CrossRef
  • Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
    Hans Gelderblom, Robin L. Jones, Suzanne George, Claudia Valverde Morales, Charlotte Benson, Jean-Yves Blay, Daniel J. Renouf, Toshihiko Doi, Axel Le Cesne, Michael Leahy, Sabine Hertle, Paola Aimone, Ulrike Brandt, Patrick Schӧffski
    British Journal of Cancer.2020; 122(8): 1158.     CrossRef
  • Life-threatening bleeding with intussusception due to gastrointestinal stromal tumor: a case report
    Min Sung Kim, In Teak Woo, Young Min Jo, Jin Hyung Lee, Byung Sam Park
    Surgical Case Reports.2019;[Epub]     CrossRef
  • Safety profile and oncological outcomes of gastric gastrointestinal stromal tumors (GISTs) robotic resection: Single center experience
    Cristina Maggioni, Atsuo Shida, Raffaello Mancini, Luigi Ioni, Graziano Pernazza
    The International Journal of Medical Robotics and Computer Assisted Surgery.2019;[Epub]     CrossRef
  • A novel technique for removing large gastric subepithelial tumors with ESD method in the subcardia region
    Bingtuan Liu, Han Chen, Weifeng Zhang, Guoxin Zhang
    Oncology Letters.2019;[Epub]     CrossRef
  • Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors
    In Sun Yoon, Ji Hoon Shin, Kichang Han, Pyo Nyun Kim, Ki Hun Kim, Yoon-Koo Kang, Heung Kyu Ko
    Korean Journal of Radiology.2018; 19(1): 54.     CrossRef
  • Robotic Gastrotomy With Intracorporeal Suture for Patients With Gastric Gastrointestinal Stromal Tumors Located at Cardia and Subcardiac Region
    Jian Zhao, Gang Wang, Zhiwei Jiang, Chuanwei Jiang, Jiang Liu, Jiahui Zhou, Jieshou Li
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2018; 28(1): e1.     CrossRef
  • A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)
    Xuechao Liu, Haibo Qiu, Zhiming Wu, Peng Zhang, Xingyu Feng, Tao Chen, Yong Li, Kaixiong Tao, Guoxin Li, Xiaowei Sun, Zhiwei Zhou
    Journal of Gastrointestinal Surgery.2018; 22(12): 2150.     CrossRef
  • Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
    Bruno Vincenzi, Margherita Nannini, Giuseppe Badalamenti, Giovanni Grignani, Elena Fumagalli, Silvia Gasperoni, Lorenzo D’Ambrosio, Lorena Incorvaia, Marco Stellato, Mariella Spalato Ceruso, Andrea Napolitano, Sergio Valeri, Daniele Santini, Giuseppe Toni
    Therapeutic Advances in Medical Oncology.2018;[Epub]     CrossRef
  • Current research and treatment for gastrointestinal stromal tumors
    Kheng Tian Lim, Kok Yang Tan
    World Journal of Gastroenterology.2017; 23(27): 4856.     CrossRef
  • Extra-gastrointestinal stromal tumor of the pancreas: report of a case
    Hyung Jun Kwon
    Annals of Hepato-Biliary-Pancreatic Surgery.2017; 21(4): 237.     CrossRef
  • The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
    Toshirou Nishida, Jean-Yves Blay, Seiichi Hirota, Yuko Kitagawa, Yoon-Koo Kang
    Gastric Cancer.2016; 19(1): 3.     CrossRef
  • Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
    Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Mo Youl Beck, In Soon Lee, Mi Jung Choi, Mi Woo Lee, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(1): 162.     CrossRef
  • Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors
    Changhoon Yoo, Min-Hee Ryu, Jungmin Jo, Inkeun Park, Baek-Yeol Ryoo, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(2): 546.     CrossRef
  • Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT)
    Changhoon Yoo, Min-Hee Ryu, Byung-Ho Nam, Baek-Yeol Ryoo, George D. Demetri, Yoon-Koo Kang
    European Journal of Cancer.2016; 52: 201.     CrossRef
  • Schwannoma of the stomach: a case report
    Aminder Singh, Ankur Mittal, Bhavna Garg, Neena Sood
    Journal of Medical Case Reports.2016;[Epub]     CrossRef
  • Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
    Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(4): 1155.     CrossRef
  • Unusual gastroduodenal intussusception secondary to a gastrointestinal stromal tumor of the gastric fundus
    Toshihide Komatsubara, Toru Zuiki, Alan Kawarai Lefor, Norio Hirota, Jun Oki
    International Journal of Surgery Open.2016; 5: 33.     CrossRef
  • Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial
    Changhoon Yoo, Yoon-Koo Kang
    Clinical Investigation.2015; 5(7): 665.     CrossRef
  • The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
    Seong Joon Park, Min-Hee Ryu, Baek-Yeol Ryoo, Young Soo Park, Byeong Seok Sohn, Hwa Jung Kim, Chan Wook Kim, Ki-Hun Kim, Chang Sik Yu, Jeong Hwan Yook, Byung Sik Kim, Yoon-Koo Kang
    Annals of Surgical Oncology.2014; 21(13): 4211.     CrossRef
  • Minimally invasive surgery for submucosal (subepithelial) tumors of the stomach
    Chang Min Lee
    World Journal of Gastroenterology.2014; 20(36): 13035.     CrossRef
  • Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
    Y-K Kang, C Yoo, B-Y Ryoo, J J Lee, E Tan, I Park, J H Park, Y J Choi, J Jo, J-S Ryu, M-H Ryu
    British Journal of Cancer.2013; 109(9): 2309.     CrossRef
  • Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
    Yoon-Koo Kang, Min-Hee Ryu, Changhoon Yoo, Baek-Yeol Ryoo, Hyun Jin Kim, Jong Jin Lee, Byung-Ho Nam, Nikhil Ramaiya, Jyothi Jagannathan, George D Demetri
    The Lancet Oncology.2013; 14(12): 1175.     CrossRef
  • Surgeon's role for gastric gastrointestinal stromal tumor in imatinib era
    Ji Yeon Park, Young-Woo Kim
    Korean Journal of Clinical Oncology.2013; 9(1): 5.     CrossRef
  • Diagnosis and Treatment of Gastrointestinal Stromal Tumor
    Yoon-Koo Kang, Dong Hoe Koo
    Korean Journal of Medicine.2013; 85(4): 341.     CrossRef
  • Surgical Treatment of Gastric Gastrointestinal Stromal Tumor
    Seong-Ho Kong, Han-Kwang Yang
    Journal of Gastric Cancer.2013; 13(1): 3.     CrossRef
  • Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan
    Chun-Nan Yeh, Tsann-Long Hwang, Ching-Shui Huang, Po-Huang Lee, Chew-Wun Wu, Ker Chen-Guo, Yi-Yin Jan, Miin-Fu Chen
    World Journal of Surgical Oncology.2012;[Epub]     CrossRef
  • 51,856 View
  • 139 Download
  • 32 Crossref
Close layer
Original Articles
Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer
Hee Seung Kim, Mi-Kyung Kim, Hak Jae Kim, Seung-Su Han, Jae Weon Kim
Cancer Res Treat. 2012;44(2):97-103.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.97
AbstractAbstract PDFPubReaderePub
PURPOSE
This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients.
MATERIALS AND METHODS
From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m2) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m2) and carboplatin (AUC 5.0) were used every 3 weeks after CCR.
RESULTS
The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60% in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports, consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings.
CONCLUSION
Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer.

Citations

Citations to this article as recorded by  
  • Radiomics feature is a risk factor for locally advanced cervical cancer treated using concurrent chemoradiotherapy based on magnetic resonance imaging: a retrospective study
    Yuan Wang, Yanyan Yu, Lina Gu, Yunfeng Sun, Jiazhuo Yan, Hongxia Zhang, Yunyan Zhang
    BMC Cancer.2025;[Epub]     CrossRef
  • Efficacy and safety of consolidation chemotherapy after adjuvant therapy in stage IB-IIA cervical cancer patients with risk factors: a retrospective single-center study
    Jiaxin Wang, Huaijuan Guo, Jingjing Yang, Jingxian Mao, Ying Wang, Ruidong Gao, Xuebing Yan, Jie Wang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • The effectiveness of consolidation chemotherapy in high-risk early-stage cervical cancer patients following concurrent chemoradiation after radical surgery
    Cong Wang, Chunli Fu, Changdong Ma, Qiuhong Qian, Fangfang He, Guangyu Zhang
    Japanese Journal of Clinical Oncology.2023; 53(2): 122.     CrossRef
  • Efficacy and safety of adjuvant chemotherapy for locally advanced cervical cancer: A systematic review and meta-analysis
    Xiao Ma, Jin Fang, Lu Zhang, Yao Huang, Hui Shen, Xiaohua Ma, Shuixing Zhang, Bin Zhang
    Critical Reviews in Oncology/Hematology.2023; 184: 103953.     CrossRef
  • The effect of consolidation chemotherapy after concurrent chemoradiation on the prognosis of locally advanced cervical cancer: a systematic review and meta-analysis
    Lan Zhong, Kemin Li, Liang Song, Rutie Yin
    Journal of Obstetrics and Gynaecology.2022; 42(5): 830.     CrossRef
  • Role of Adjuvant Chemotherapy After Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer
    Lingna Kou, Tao Zhang, Xiling Yang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin Li
    Future Oncology.2022; 18(16): 1917.     CrossRef
  • Integration of Consolidation Chemotherapy After Concurrent Chemoradiation in the Treatment of Locally Advanced Uterine Cervical Cancer
    V. S. Haritha, Laxmi Singotia, Rajesh Jain, A. K. Saxena, Shyamji Rawat, Lalit Patel
    Indian Journal of Gynecologic Oncology.2022;[Epub]     CrossRef
  • A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy
    Ning Wu, Xing Su, Honglin Song, Ying Li, Fei Gu, Xiaoge Sun, Xiaofan Li, Guanghui Cheng
    Cancer Control.2021;[Epub]     CrossRef
  • Adjuvant Systemic Therapy after Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis
    Nanda Horeweg, Prachi Mittal, Patrycja L. Gradowska, Ingrid Boere, Supriya Chopra, Remi A. Nout
    Cancers.2021; 13(8): 1880.     CrossRef
  • How should we stage and tailor treatment strategy in locally advanced cervical cancer? Imaging versus para-aortic surgical staging
    Alejandra Martinez, Martina Aida Angeles, Denis Querleu, Gwenael Ferron, Christophe Pomel
    International Journal of Gynecological Cancer.2020; 30(9): 1434.     CrossRef
  • Clinical Analysis of Apatinib in the Treatment of Patients with Residual Tumor after Radical Chemoradiotherapy for Locally Advanced Cervical Cancer
    Jun Jiang, Wei Hong Wei, Tao Xu
    Journal of Cancer Research Updates.2020; 9(1): 20.     CrossRef
  • Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients
    Seiji Mabuchi, Fumiaki Isohashi, Mika Okazawa, Fuminori Kitada, Shintaro Maruoka, Kazuhiko Ogawa, Tadashi Kimura
    Journal of Gynecologic Oncology.2017;[Epub]     CrossRef
  • Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer
    Kyungmi Yang, Won Park, Seung Jae Huh, Duk-Soo Bae, Byoung-Gie Kim, Jeong-Won Lee
    Radiation Oncology Journal.2017; 35(1): 39.     CrossRef
  • Substantieller Vorteil durch CT-geplante HDR-Brachytherapie bei Zervixkarzinompatientinnen im Vergleich zu historischen Serien bezüglich lokaler Kontrolle und Toxizität?
    Simone Marnitz
    Strahlentherapie und Onkologie.2017; 193(3): 236.     CrossRef
  • CT-geplante HDR-Brachytherapie
    Simone Marnitz-Schulze
    InFo Onkologie.2017; 20(4): 10.     CrossRef
  • Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical Cancer
    Jeanny Kwon, Keun-Yong Eom, In Ah Kim, Jae-Sung Kim, Young-Beom Kim, Jae Hong No, Kidong Kim
    Cancer Research and Treatment.2016; 48(2): 632.     CrossRef
  • A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes
    Seiji Mabuchi, Fumiaki Isohashi, Takeshi Yokoi, Masahiko Takemura, Kiyoshi Yoshino, Yasuhiko Shiki, Kimihiko Ito, Takayuki Enomoto, Kazuhiko Ogawa, Tadashi Kimura
    Gynecologic Oncology.2016; 141(2): 240.     CrossRef
  • Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer
    Yu Chang, Zhi-Yong Yang, Gui-Ling Li, Qin Li, Qin Yang, Ji-Quan Fan, Ying-Chao Zhao, Ying-Qiu Song, Gang Wu
    International Journal of Gynecological Cancer.2016; 26(4): 770.     CrossRef
  • Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy
    Wenze Sun, Tao Wang, Fan Shi, Jiquan Wang, Juan Wang, Beina Hui, Yingbing Zhang, Jinli Lu, Hongwei Chen, Zi Liu
    BMC Cancer.2015;[Epub]     CrossRef
  • Time-window of early detection of response to concurrent chemoradiation in cervical cancer by using diffusion-weighted MR imaging: a pilot study
    Ying Liu, Haoran Sun, Renju Bai, Zhaoxiang Ye
    Radiation Oncology.2015;[Epub]     CrossRef
  • Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer
    Siriwan Tangjitgamol, Kanyarat Katanyoo, Malinee Laopaiboon, Pisake Lumbiganon, Sumonmal Manusirivithaya, Busaba Supawattanabodee
    Cochrane Database of Systematic Reviews.2014;[Epub]     CrossRef
  • Comparison of Clinical Efficacy of Three Different Neoadjuvant Approaches (Chemotherapy Combined Vaginal Intracavitary Irradiation, Neoadjuvant Chemotherapy Alone or Radiotherapy) Combined with Surgery for Patients with Stage Ib2 and IIa2 Cervical Cancer
    Jian-Hong Fu, Zhan Gao, Chen-Chen Ren, Yong-Gang Shi
    Asian Pacific Journal of Cancer Prevention.2013; 14(4): 2377.     CrossRef
  • A Phase I Study of Concurrent Weekly Carboplatin and Paclitaxel Combined With Intensity-Modulated Pelvic Radiotherapy as an Adjuvant Treatment for Early-Stage Cervical Cancer Patients With Positive Pelvic Lymph Nodes
    Seiji Mabuchi, Ryoko Takahashi, Fumiaki Isohashi, Takeshi Yokoi, Kimihiko Ito, Tateki Tsutui, Toshiyuki Ogata, Yasuo Yoshioka, Kazuhiko Ogawa, Tadashi Kimura
    International Journal of Gynecological Cancer.2013; 23(7): 1279.     CrossRef
  • 11,032 View
  • 97 Download
  • 23 Crossref
Close layer
Preoperative Concurrent Chemoradiotherapy for Locally Advanced Rectal Cancer: Treatment Outcomes and Analysis of Prognostic Factors
Moonkyoo Kong, Seong Eon Hong, Woo Suk Choi, Si-Young Kim, Jinhyun Choi
Cancer Res Treat. 2012;44(2):104-112.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.104
AbstractAbstract PDFPubReaderePub
PURPOSE
This study was designed to investigate the long-term oncologic outcomes for locally advanced rectal cancer patients after treatment with preoperative concurrent chemoradiotherapy followed by total mesorectal excision, and to identify prognostic factors that affect survival and pathologic response.
MATERIALS AND METHODS
From June 1996 to June 2009, 135 patients with locally advanced rectal cancer were treated with preoperative concurrent chemoradiotherapy followed by total mesorectal excision at Kyung Hee University Hospital. Patient data was retrospectively collected and analyzed in order to determine the treatment outcomes and identify prognostic factors for survival.
RESULTS
The median follow-up time was 50 months (range, 4.5 to 157.8 months). After preoperative chemoradiotherapy, sphincter preservation surgery was accomplished in 67.4% of whole patients. A complete pathologic response was achieved in 16% of patients. The estimated 5- and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for all patients was 82.7% and 75.7%, 76.8% and 71.9%, 67.9% and 63.3%, respectively. The estimated 5- and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for pathologic complete responders was 100% and 100%, 100% and 88.9%, 95.5% and 95.5%, respectively. In the multivariate analysis, pathologic complete response was significantly associated with overall survival. The predictive factor for pathologic complete response was pretreatment clinical stage.
CONCLUSION
Preoperative chemoradiotherapy for locally advanced rectal cancer resulted in a high rate of overall survival, sphincter preservation, down-staging, and pathologic complete response. The patients achieving pathologic complete response had very favorable outcomes. Pathologic complete response was a significant prognostic factor for overall survival and the significant predictive factor for a pathologic complete response was pretreatment clinical stage.

Citations

Citations to this article as recorded by  
  • Analysis of clinical and pathological prognostic factors of survival in rectal adenocarcinoma treated with preoperative radiochemotherapy
    Sarhan Sydney Saad, Nora Forones, Gaspar Lopes Filho, Jaques Waisberg, Elesiario Caetano Júnior, Ricardo Artigiani-Neto, Delcio Matos
    Acta Cirúrgica Brasileira.2025;[Epub]     CrossRef
  • The optimal time interval between neoadjuvant chemoradiotherapy and surgery for patients with an unfavorable pathological response in locally advanced rectal cancer: a retrospective cohort study
    Litao Wang, Jianyong Fan, Yaqi Guo, Shipeng Shang, Han Gao, Jianfei Xu, Peng Gao, Enrui Liu
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Characteristics of Patients Presented With Metastases During or After Completion of Chemoradiation Therapy for Locally Advanced Rectal Cancer: A Case Series
    Radwan Torky, Mohammed Alessa, Ho Seung Kim, Ahmed Sakr, Eman Zakarneh, Fozan Sauri, Heejin Bae, Nam Kyu Kim
    Annals of Coloproctology.2021; 37(3): 186.     CrossRef
  • A prospective analysis of the diagnostic accuracy of 3 T MRI, CT and endoscopic ultrasound for preoperative T staging of potentially resectable esophageal cancer
    Jia Guo, Zhaoqi Wang, Jianjun Qin, Hongkai Zhang, Wentao Liu, Yan Zhao, Yanan Lu, Xu Yan, Zhongxian Zhang, Ting Zhang, Shouning Zhang, Nickel Marcel Dominik, Ihab R. Kamel, Hailiang Li, Jinrong Qu
    Cancer Imaging.2020;[Epub]     CrossRef
  • Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer
    Jaesung Heo, Mison Chun, O Kyu Noh, Young-Taek Oh, Kwang Wook Suh, Jun Eun Park, Oyeon Cho
    Cancer Research and Treatment.2016; 48(1): 232.     CrossRef
  • Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer
    Ikuko Kato, Gregory Dyson, Michael Snyder, Hyeong-Reh Kim, Richard K. Severson
    Journal of Radiation Oncology.2016; 5(3): 279.     CrossRef
  • JOURNAL CLUB: Preoperative MRI Evaluation of Primary Rectal Cancer: Intrasubject Comparison With and Without Rectal Distention
    Feng Ye, Hongmei Zhang, Xiao Liang, Han Ouyang, Xinming Zhao, Chunwu Zhou
    American Journal of Roentgenology.2016; 207(1): 32.     CrossRef
  • Utility of high resolution MRI for pre-operative staging of rectal carcinoma, involvement of the mesorectal fascia and circumferential resection margin
    Tamir A. Hassan, Hossam M. Abdel-Rahman, Hala Yehia Ali
    The Egyptian Journal of Radiology and Nuclear Medicine.2016; 47(4): 1243.     CrossRef
  • Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer
    Junzhong Lin, Jianhong Peng, Aiham Qdaisat, Liren Li, Gong Chen, Zhenhai Lu, Xiaojun Wu, Yuanhong Gao, Zhifan Zeng, Peirong Ding, Zhizhong Pan
    Journal of Cancer Research and Clinical Oncology.2016; 142(12): 2551.     CrossRef
  • Complete radiotherapy response in rectal cancer: A review of the evidence
    Daniel G Couch
    World Journal of Gastroenterology.2016; 22(2): 467.     CrossRef
  • The Value of High-Resolution MRI Technique in Patients with Rectal Carcinoma: Pre-Operative Assessment of Mesorectal Fascia Involvement, Circumferential Resection Margin and Local Staging
    Samah Kohla
    Polish Journal of Radiology.2015; 80: 115.     CrossRef
  • Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study
    Gennaro Galizia, Eva Lieto, Ferdinando De Vita, Francesca Ferraraccio, Anna Zamboli, Andrea Mabilia, Annamaria Auricchio, Paolo Castellano, Vincenzo Napolitano, Michele Orditura
    International Journal of Colorectal Disease.2014; 29(1): 89.     CrossRef
  • Accuracy of High-Resolution MRI with Lumen Distention in Rectal Cancer Staging and Circumferential Margin Involvement Prediction
    Elsa Iannicelli, Sara Di Renzo, Mario Ferri, Emanuela Pilozzi, Marco Di Girolamo, Alessandra Sapori, Vincenzo Ziparo, Vincenzo David
    Korean Journal of Radiology.2014; 15(1): 37.     CrossRef
  • EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum
    Cornelis J.H. van de Velde, Petra G. Boelens, Josep M. Borras, Jan-Willem Coebergh, Andres Cervantes, Lennart Blomqvist, Regina G.H. Beets-Tan, Colette B.M. van den Broek, Gina Brown, Eric Van Cutsem, Eloy Espin, Karin Haustermans, Bengt Glimelius, Lene H
    European Journal of Cancer.2014; 50(1): 1.e1.     CrossRef
  • Eine intensivierte Chemotherapie erhöht die Effektivität nicht, oder doch?
    Gunther Klautke
    Info Onkologie.2014; 17(6): 17.     CrossRef
  • Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy
    Nir Wasserberg, Yulia Kundel, Ofer Purim, Andrei Keidar, Hanoch Kashtan, Eran Sadot, Eyal Fenig, Baruch Brenner
    Radiation Oncology.2014;[Epub]     CrossRef
  • Metformin use and improved response to therapy in rectal cancer
    Heath D. Skinner, Christopher H. Crane, Christopher R. Garrett, Cathy Eng, George J. Chang, John M. Skibber, Miguel A. Rodriguez‐Bigas, Patrick Kelly, Vlad C. Sandulache, Marc E. Delclos, Sunil Krishnan, Prajnan Das
    Cancer Medicine.2013; 2(1): 99.     CrossRef
  • 12,815 View
  • 54 Download
  • 17 Crossref
Close layer
Trends in Cancer Screening Rates among Korean Men and Women: Results from the Korean National Cancer Screening Survey (KNCSS), 2004-2011
Boyoung Park, Kui Son Choi, Yoon Young Lee, Jae Kwan Jun, Hong Gwan Seo
Cancer Res Treat. 2012;44(2):113-120.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.113
AbstractAbstract PDFPubReaderePub
PURPOSE
The Korean National Cancer Screening Survey (KNCSS) is a nationwide survey conducted annually, since 2004. This study was conducted in order to report on trends in rates of cancer screening for five major cancers-stomach, liver, colorectal, breast, and cervix uteri in Korea.
MATERIALS AND METHODS
Data collected by the KNCSS between 2004 and 2011 were used in this study. The eligible study population included cancer-free men who were 40 years old and over, and women who were 30 years old and over. Lifetime screening rate, screening rate with recommendation, and changes in annual rates were calculated.
RESULTS
Both lifetime screening rates and screening rates with recommendation have increased since 2004. On average, screening rates with recommendation have shown an annual increase of 4.2% (95% CI, 3.3 to 5.2%) for stomach cancer, 1.1% (95% CI, -0.5 to 2.7%) for liver cancer, 2.2% (95% CI, 0.8 to 3.6%) for colorectal cancer, 4.0% (95% CI, 3.0 to 4.9%) for breast cancer, and 0.2% (95% CI, -0.9 to 1.3%) for cervical cancer. Increases in rates of cancer screening, with the exception of liver and cervical cancers, were significant, and screening rates for stomach and breast cancer in particular showed a marked increase.
CONCLUSION
Cancer screening rates among Koreans showed a consistent increase from 2004 to 2011 and rates of screening for gastric, breast, and cervical cancer are approaching 70%.

Citations

Citations to this article as recorded by  
  • Utilization of colorectal cancer screening tests: a systematic review and time trend analysis of nationally representative data
    Idris Ola, Rafael Cardoso, Michael Hoffmeister, Hermann Brenner
    eClinicalMedicine.2024; 75: 102783.     CrossRef
  • Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts
    Sang Il Choi, Yuri Cho, Moran Ki, Bo Hyun Kim, In Joon Lee, Tae Hyun Kim, Seong Hoon Kim, Young Hwan Koh, Hyun Beom Kim, Eun Kyung Hong, Chang-Min Kim, Joong-Won Park, Hamidreza Karimi-Sari
    PLOS ONE.2022; 17(3): e0265668.     CrossRef
  • Clinical subtypes and prognosis in breast cancer according to parity: a nationwide study in Korean Breast Cancer Society
    Sungmin Park, Byung In Moon, Se Jeong Oh, Han-Byoel Lee, Min-Ki Seong, Seokwon Lee, Kyung Do Byun, Seung Pil Jung, Soo Youn Bae
    Breast Cancer Research and Treatment.2019; 173(3): 679.     CrossRef
  • Women’s knowledge, awareness and attitudes toward newly implemented national HPV-based screening in Turkey
    Hasan Aykut Tuncer, Serap Firtina Tuncer
    Journal of Cancer Policy.2019; 22: 100205.     CrossRef
  • Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus‐endemic population
    Bo Hyun Kim, Young‐Suk Lim, Eun‐Yang Kim, Hyun‐Joo Kong, Young‐Joo Won, Seungbong Han, Sohee Park, Jae Seok Hwang
    Journal of Gastroenterology and Hepatology.2018; 33(2): 475.     CrossRef
  • Clinicopathologic score predicting lymph node metastasis in T1 gastric cancer
    Thuy B. Tran, David J. Worhunsky, Malcolm H. Squires, Linda X. Jin, Gaya Spolverato, Konstantinos I. Votanopoulos, Sharon M. Weber, Carl Schmidt, Edward A. Levine, Ryan C. Fields, Timothy M. Pawlik, Shishir K. Maithel, Jeffrey A. Norton, George A. Poultsi
    Surgery.2018; 163(4): 889.     CrossRef
  • Risk factors for developing liver cancer in people with and without liver disease
    Jae Kyung Suh, Jayoun Lee, Jeong-Hoon Lee, Sangjin Shin, Ha jin Tchoe, Jin-Won Kwon, Jason Blackard
    PLOS ONE.2018; 13(10): e0206374.     CrossRef
  • Disparities in the utilisation of preventive health services by the employment status: An analysis of 2007-2012 South Korean national survey
    SangJune Kim, Jee Hey Song, Yoo Min Oh, Sang Min Park, Geofrey Musinguzi
    PLOS ONE.2018; 13(12): e0207737.     CrossRef
  • Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients
    Joon Yeul Nam, Jeong-Hoon Lee, Hwi Young Kim, Jieun E. Kim, Dong Hyeon Lee, Young Chang, Hyeki Cho, Jeong-Ju Yoo, Minjong Lee, Young Youn Cho, Yuri Cho, EunJu Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Chi-Ling Chen
    PLOS ONE.2017; 12(1): e0166188.     CrossRef
  • Prognostic value of ABO blood types in young patients with breast cancer; a nationwide study in Korean Breast Cancer Society
    Sungmin Park, Ku Sang Kim, Jeong-Soo Kim, Wonshik Han, Byeong-Woo Park, Seokwon Lee, Ye Won Jeon, Se Kyung Lee, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam
    Medical Oncology.2017;[Epub]     CrossRef
  • Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society
    Jai Min Ryu, Jonghan Yu, Seung Il Kim, Ku Sang Kim, Hyeong-Gon Moon, Jung Eun Choi, Joon Jeong, Kyung Do Byun, Seok Jin Nam, Jeong Eon Lee, Se Kyung Lee, Seok Won Kim
    Breast Cancer Research and Treatment.2017; 166(3): 833.     CrossRef
  • Cancer literacy as a mediator for cancer screening behaviour in Korean adults
    Hee Yun Lee, Taeho Greg Rhee, Nam Keol Kim
    Health & Social Care in the Community.2016; 24(5): e34.     CrossRef
  • Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society
    Jai Min Ryu, Hyouk Jin Lee, Tae in Yoon, Eun Sook Lee, Soo Jung Lee, Jin Hyang Jung, Byung Joo Chae, Seok Jin Nam, Jeong Eon Lee, Se Kyung Lee, Soo Youn Bae, Jonghan Yu, Seok Won Kim
    Breast Cancer Research and Treatment.2016; 159(3): 489.     CrossRef
  • Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B
    Jae-Jun Shim, In Hwan Oh, Sang Bae Kim, Jung Wook Kim, Chang Kyun Lee, Jae Young Jang, Ju-Seog Lee, Byung-Ho Kim
    Gut and Liver.2016; 10(6): 962.     CrossRef
  • Long-term outcome comparison of endoscopic resection and surgery in early gastric cancer meeting the absolute indication for endoscopic resection
    Il Ju Choi, Jun Ho Lee, Young-Il Kim, Chan Gyoo Kim, Soo-Jeong Cho, Jong Yeul Lee, Keun Won Ryu, Byung-Ho Nam, Myeong-Cherl Kook, Young-Woo Kim
    Gastrointestinal Endoscopy.2015; 81(2): 333.     CrossRef
  • Robotic distal subtotal gastrectomy with D2 lymphadenectomy for gastric cancer patients with high body mass index: comparison with conventional laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy
    Juhan Lee, Yoo-Min Kim, Yanghee Woo, Kazutaka Obama, Sung Hoon Noh, Woo Jin Hyung
    Surgical Endoscopy.2015; 29(11): 3251.     CrossRef
  • High liver fibrosis index FIB‐4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers
    Beomseok Suh, Sehhoon Park, Dong Wook Shin, Jae Moon Yun, Hyung‐Kook Yang, Su Jong Yu, Cheong‐Il Shin, Jin‐Soo Kim, Eunmi Ahn, Hyejin Lee, Jin Ho Park, BeLong Cho
    Hepatology.2015; 61(4): 1261.     CrossRef
  • Endoscopic Resection for Synchronous Esophageal Squamous Cell Carcinoma and Gastric Adenocarcinoma in Early Stage Is a Possible Alternative to Surgery
    Se Jeong Park, Ji Yong Ahn, Hwoon-Yong Jung, Shin Na, So-Eun Park, Mi-Young Kim, Kwi-Sook Choi, Jeong Hoon Lee, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee, Jin-Ho Kim, Seungbong Han
    Gut and Liver.2015; 9(1): 59.     CrossRef
  • Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB‐4 liver fibrosis index
    Beomseok Suh, Jae Moon Yun, Sehhoon Park, Dong Wook Shin, Tae Hoon Lee, Hyung‐Kook Yang, Eunmi Ahn, Hyejin Lee, Jin Ho Park, BeLong Cho
    Cancer.2015; 121(21): 3818.     CrossRef
  • Is microsatellite instability a prognostic marker in gastric cancer?: A systematic review with meta-analysis
    Yoon Young Choi, Jung Min Bae, Ji Yeong An, In Gyu Kwon, In Cho, Hyun Beak Shin, Tanaka Eiji, Mohammad Aburahmah, Hyung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh
    Journal of Surgical Oncology.2014; 110(2): 129.     CrossRef
  • Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition
    Sang Gyun Kim, Hye‐Kyung Jung, Hang Lak Lee, Jae Young Jang, Hyuk Lee, Chan Gyoo Kim, Woon Geon Shin, Ein Soon Shin, Yong Chan Lee
    Journal of Gastroenterology and Hepatology.2014; 29(7): 1371.     CrossRef
  • Effects of Screening on Gastric Cancer Management: Comparative Analysis of the Results in 2006 and in 2011
    Yun Gyoung Kim, Seong-Ho Kong, Seung-Young Oh, Kyung-Goo Lee, Yun-Suhk Suh, Jun-Young Yang, Jeongmin Choi, Sang Gyun Kim, Joo-Sung Kim, Woo Ho Kim, Hyuk-Joon Lee, Han-Kwang Yang
    Journal of Gastric Cancer.2014; 14(2): 129.     CrossRef
  • Breast Cancer Screening Knowledge and Perceived Health Beliefs among Immigrant Women in Korea
    Jiyoung Kim, Se Kyung Lee, Jeonghui Lee, Min-Young Choi, Seung Pil Jung, Min Kook Kim, Sangmin Kim, Seok Jin Nam, Jeong Eon Lee, Won Ho Kil
    Journal of Breast Cancer.2014; 17(3): 279.     CrossRef
  • Factors Associated with Organized and Opportunistic Cancer Screening: Results of the Korea National Health and Nutrition Examination Survey (KNHANES) 2007-2011
    Minsun Kang, Ki-Bong Yoo, Eun-Cheol Park, Kisung Kwon, Gaeun Kim, Doo Ree Kim, Jeoung A Kwon
    Asian Pacific Journal of Cancer Prevention.2014; 15(7): 3279.     CrossRef
  • The Korean National Liver Cancer Surveillance Program: Experience of a Single Healthcare Center in 2011
    Jae-Jun Shim, Hyun Jin Park, Jung-Wook Kim, Eun Jung Hwang, Chang Kyun Lee, Jae Young Jang, Seong Jin Park, Hyun Rim Choi, Byung-Ho Kim
    Korean Journal of Medicine.2013; 84(5): 672.     CrossRef
  • Relationship between Social Network and Stage of Adoption of Gastric Cancer Screening among the Korean Population
    Myung Ha Lee, Kui Son Choi, Yoon Young Lee, Mina Suh, Jae Kwan Jun
    Asian Pacific Journal of Cancer Prevention.2013; 14(10): 6095.     CrossRef
  • Cancer Screening in Korea, 2012: Results from the Korean National Cancer Screening Survey
    Mina Suh, Kui Son Choi, Yoon Young Lee, Boyoung Park, Jae Kwan Jun
    Asian Pacific Journal of Cancer Prevention.2013; 14(11): 6459.     CrossRef
  • Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010
    Myong Cheol Lim, Eun-Kyeong Moon, Aesun Shin, Kyu-Won Jung, Young-Joo Won, Sang Soo Seo, Sokbom Kang, Jae-Weon Kim, Joo-Young Kim, Sang-Yoon Park
    Journal of Gynecologic Oncology.2013; 24(4): 298.     CrossRef
  • Guidelines for the Diagnosis and Treatment ofHelicobacter pyloriInfection in Korea, 2013 Revised Edition
    Sang Gyun Kim, Hye-Kyung Jung, Hang Lak Lee, Jae Young Jang, Hyuk Lee, Chan Gyoo Kim, Woon Geon Shin, Ein Soon Shin, Yong Chan Lee
    The Korean Journal of Gastroenterology.2013; 62(1): 3.     CrossRef
  • Knowledge of Colorectal Cancer Screening among Young Malaysians
    Redhwan Ahmed Al-Naggar, Yuri V. Bobryshev
    Asian Pacific Journal of Cancer Prevention.2013; 14(3): 1969.     CrossRef
  • Prevalence of and Risk Factors for Gastrointestinal Diseases in Korean Americans and Native Koreans Undergoing Screening Endoscopy
    Hee Sun Kim, Su Jung Baik, Kyung Hee Kim, Cho Rong Oh, Jung Hyun Lee, Wan Jae Jo, Hye Kyoung Kim, Eun Young Kim, Min Jung Kim
    Gut and Liver.2013; 7(5): 539.     CrossRef
  • The National Cancer Screening Program for Breast Cancer in the Republic of Korea: Is it Cost-Effective?
    Moon Hae Kang, Eun-Cheol Park, Kui Son Choi, MiNa Suh, Jae Kwan Jun, Eun Cho
    Asian Pacific Journal of Cancer Prevention.2013; 14(3): 2059.     CrossRef
  • Factors Associated with Compliance with Recommendations for Liver Cancer Screening in Korea: A Nationwide Survey in Korea
    Boyoung Park, Kui Son Choi, Mina Suh, Ji-Yeon Shin, Jae Kwan Jun, Hiromu Suzuki
    PLoS ONE.2013; 8(6): e68315.     CrossRef
  • 12,616 View
  • 60 Download
  • 33 Crossref
Close layer
Apolipoprotein E (APOE) Polymorphisms and Susceptibility to Breast Cancer: A Meta-Analysis
Mostafa Saadat
Cancer Res Treat. 2012;44(2):121-126.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.121
AbstractAbstract PDFPubReaderePub
PURPOSE
Apolipoprotein E (APOE, MIM: 107741) has three functionally distinct isoforms of the protein (E2, E3, and E4), encoded by corresponding alleles epsilon2, epsilon3, and epsilon4, which have been well described. Findings from previous studies investigating association between APOE polymorphisms and breast cancer risk have been inconsistent. The present meta-analysis was conducted in order to investigate association of APOE polymorphisms with risk of breast cancer.
MATERIALS AND METHODS
Several electronic databases were used for identification of studies containing information on APOE polymorphisms and breast cancer risk published up to January 2012. We identified 10 eligible studies, including 3,835 subjects (2008 patients, and 1,827 healthy controls), that reported on polymorphisms of APOE and risk of breast cancer. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were obtained using a fixed and random-effects models.
RESULTS
Among studies reported from Asia, an association of the epsilon4 allele with increased risk of breast cancer, in comparison with the epsilon3 allele, was observed (OR, 1.56; 95% CI, 1.19 to 2.04; p=0.001). It should be noted that allele epsilon2 showed no association with breast cancer risk. Among Caucasians, neither the epsilon4 (OR, 0.99; 95% CI, 0.83 to 1.17; p=0.917) nor the epsilon2 (OR, 0.92; 95% CI, 0.72 to 1.17; p=0.514) allele showed an association with susceptibility to breast cancer, when compared with the epsilon3 allele. Carriers of the epsilon4 allele (E4E4, E4E3, and E4E2 genotypes), in comparison with the E3E3 genotype, showed an association with elevated risk of breast cancer only among Asians (OR, 1.75; 95% CI, 1.23 to 2.47; p=0.002). No publication bias was detected.
CONCLUSION
This meta-analysis suggest that the APOEepsilon4 allele is a low-penetrant risk factor for development of breast cancer.

Citations

Citations to this article as recorded by  
  • Single‐cell RNA‐sequencing and spatial transcriptomic analysis reveal a distinct population of APOE− cells yielding pathological lymph node metastasis in papillary thyroid cancer
    Guohui Xiao, Rongli Xie, Jianhua Gu, Yishu Huang, Min Ding, Dongjie Shen, Jiqi Yan, Jianming Yuan, Qiong Yang, Wen He, Siyu Xiao, Haizhen Chen, Dan Xu, Jian Wu, Jian Fei
    Clinical and Translational Medicine.2025;[Epub]     CrossRef
  • Curious Dichotomies of Apolipoprotein E Function in Alzheimer’s Disease and Cancer—One Explanatory Mechanism of Inverse Disease Associations?
    Claire M. Perks, Rachel M. Barker, Mai Alhadrami, Omar Alkahtani, Emily Gill, Mary Grishaw, Abigail J. Harland, Peter Henley, Haonan Li, Ellie O’Sullivan, Gideon Stone, Xiaoyu Su, Patrick G. Kehoe
    Genes.2025; 16(3): 331.     CrossRef
  • Association between three common genetic polymorphisms of xeroderma pigmentosum complementation group C (XPC) and susceptibility to opium dependency
    Arghavan Qasemian-Talgard, Mostafa Saadat
    Egyptian Journal of Medical Human Genetics.2024;[Epub]     CrossRef
  • The Role of Apolipoproteins in the Commonest Cancers: A Review
    Nour M. Darwish, Mooza Kh. Al-Hail, Youssef Mohamed, Rafif Al Saady, Sara Mohsen, Amna Zar, Layla Al-Mansoori, Shona Pedersen
    Cancers.2023; 15(23): 5565.     CrossRef
  • Association of Apolipoprotein E Gene Polymorphism with Type 2 Diabetic Nephropathy in the Southern Chinese Population
    Caiyan Gan, Yinmei Zhang, Xianyan Zhang, Qionghui Huang, Xuemin Guo
    International Journal of General Medicine.2023; Volume 16: 5549.     CrossRef
  • Ferroptosis-Related APOE, BCL3 and ALOX5AP Gene Polymorphisms are Associated with the Risk of Thyroid Cancer
    Zhifu Xiao, Haixia Zhao
    Pharmacogenomics and Personalized Medicine.2022; Volume 15: 157.     CrossRef
  • Circulating HDL and Non-HDL Associated Apolipoproteins and Breast Cancer Severity
    Christine Bobin-Dubigeon, Hassan Nazih, Valentin Blanchard, Mikaël Croyal, Jean-Marie Bard
    Journal of Clinical Medicine.2022; 11(5): 1345.     CrossRef
  • In silico identification of single nucleotide variations at CpG sites regulating CpG island existence and size
    Nivas Shyamala, Chaitra Lava Kongettira, Kaushik Puranam, Keerthi Kupsal, Ramanjaneyulu Kummari, Chiranjeevi Padala, Surekha Rani Hanumanth
    Scientific Reports.2022;[Epub]     CrossRef
  • Effects of APOE gene ε4 allele on serum lipid profiles and risk of cardiovascular disease and tumorigenesis in southern Chinese population
    Caiyan Gan, Yinmei Zhang, Fei Liang, Xuemin Guo, Zhixiong Zhong
    World Journal of Surgical Oncology.2022;[Epub]     CrossRef
  • Apolipoproteins: New players in cancers
    Yingcheng He, Jianrui Chen, Yanbing Ma, Hongping Chen
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Comprehensive Identification of Potential Crucial Genes and miRNA‐mRNA Regulatory Networks in Papillary Thyroid Cancer
    Ben-yu Nan, Guo-Feng Xiong, Zi-Rui Zhao, Xi Gu, Xin-Sheng Huang, Monica Fedele
    BioMed Research International.2021;[Epub]     CrossRef
  • Glaucoma as Neurodegeneration in the Brain
    Jane W Chan, Noel CY Chan, Alfredo A Sadun
    Eye and Brain.2021; Volume 13: 21.     CrossRef
  • The association of genetic polymorphisms with neuroconnectivity in breast cancer patients
    Rebecca A. Harrison, Vikram Rao, Shelli R. Kesler
    Scientific Reports.2021;[Epub]     CrossRef
  • Evaluation of associations of GSTM1/GSTT1 null genotypes with the susceptibility to age-related macular degeneration: A meta-analysis
    Mostafa Saadat
    Scripta Medica.2021; 52(1): 38.     CrossRef
  • Recent Advances in Diagnostic and Therapeutic Approaches for Breast Cancer: A Comprehensive Review
    Fatima Noor, Ayesha Noor, Ali Raza Ishaq, Iqra Farzeen, Muhammad Hamzah Saleem, Kanwal Ghaffar, Muhammad Farhan Aslam, Sidra Aslam, Jen-Tsung Chen
    Current Pharmaceutical Design.2021; 27(20): 2344.     CrossRef
  • Risk of Alzheimer’s Disease in Cancer Patients: Analysis of Mortality Data from the US SEER Population-Based Registries
    Roman Mezencev, Yury O. Chernoff
    Cancers.2020; 12(4): 796.     CrossRef
  • Association Between GSTP1 Ile105Val Genetic Polymorphism and Dependency to Heroin and Opium
    Majede Rezaei, Mostafa Saadat
    Biochemical Genetics.2019; 57(2): 214.     CrossRef
  • ε3/4 genotype of the apolipoprotein E is associated with higher risk of Alzheimer's disease in patients with type 2 diabetes mellitus
    Yi Tang, Ya-Mei Li, Ming Zhang, Yan-Qiu Chen, Qin Sun
    Gene.2019; 703: 65.     CrossRef
  • Association of ApoE haplotype with clinical evidence of pituitary adenoma
    Agne Sidaraite, Alvita Vilkeviciute, Brigita Glebauskiene, Loresa Kriauciuniene, Dalia Zaliuniene, Rasa Liutkeviciene
    Gene.2019; 706: 154.     CrossRef
  • The risk of cancer in the offspring and parental length of life
    Ruby Del Risco Kollerud, Karl Gerhard Blaasaas, Bjørgulf Claussen, Bente Oftedal, Øyvind Næss
    Cancer Epidemiology.2017; 48: 8.     CrossRef
  • Lack of association between two genetic polymorphisms of SOD2 (rs2758339 and rs5746136) and the risk of opium dependency
    Fariba Boroumand, Mostafa Saadat
    Polish Annals of Medicine.2017; 24(2): 194.     CrossRef
  • Association between ABO and Rh Blood Groups and Risk of Preeclampsia: A Case-Control Study from Iran
    Firoozeh Aghasadeghi, Mostafa Saadat
    Open Access Macedonian Journal of Medical Sciences.2017; 5(2): 173.     CrossRef
  • Apolipoprotein E epsilon 2 allele and low serum cholesterol as risk factors for gastric cancer in a Chinese Han population
    Ranran Kang, Ping Li, Tingting Wang, Xinxiu Li, Zichen Wei, Zhenlian Zhang, Li Zhong, Longlong Cao, Michael G. Heckman, Yun-Wu Zhang, Huaxi Xu, Changming Huang, Guojun Bu, Xiao-Fen Chen
    Scientific Reports.2016;[Epub]     CrossRef
  • Serum levels of apolipoprotein E correlates with disease progression and poor prognosis in breast cancer
    Xiangdong Xu, Jianxin Wan, Linjing Yuan, Junhui Ba, Pinning Feng, Weiqing Long, Hao Huang, Pingjuan Liu, Yuesu Cai, Min Liu, Jinmei Luo, Laisheng Li
    Tumor Biology.2016; 37(12): 15959.     CrossRef
  • Association of the Apolipoprotein E 2 Allele with Concurrent Occurrence of Endometrial Hyperplasia and Endometrial Carcinoma
    Tatiana I. Ivanova, Ludmila I. Krikunova, Nikolay I. Ryabchenko, Liana S. Mkrtchyan, Vera A. Khorokhorina, Lyubov E. Salnikova
    Oxidative Medicine and Cellular Longevity.2015; 2015: 1.     CrossRef
  • Apolipoprotein E ( ApoE ) polymorphism is related to differences in potential fertility in women: a case of antagonistic pleiotropy?
    Grazyna Jasienska, Peter T. Ellison, Andrzej Galbarczyk, Michal Jasienski, Malgorzata Kalemba-Drozdz, Maria Kapiszewska, Ilona Nenko, Inger Thune, Anna Ziomkiewicz
    Proceedings of the Royal Society B: Biological Sciences.2015; 282(1803): 20142395.     CrossRef
  • Analysis of differentially expressed novel post-translational modifications of plasma apolipoprotein E in Taiwanese females with breast cancer
    Yih-Huei Uen, Chen-Chung Liao, Jung-Chun Lin, Yi-Hsuan Pan, Yi-Chung Liu, You-Chia Chen, Wei-Jung Chen, Chih-Chun Tai, Kuan-Wei Lee, Yun-Ru Liu, Hung-Tse Lin, Ching-Yu Lin
    Journal of Proteomics.2015; 126: 252.     CrossRef
  • Sleep apnea and the subsequent risk of breast cancer in women: a nationwide population-based cohort study
    Wei-Pin Chang, Mu-En Liu, Wei-Chiao Chang, Albert C. Yang, Yan-Chiou Ku, Jei-Tsung Pai, Yea-Wen Lin, Shih-Jen Tsai
    Sleep Medicine.2014; 15(9): 1016.     CrossRef
  • Association between apolipoprotein E genotype and cancer susceptibility: a meta-analysis
    R. Anand, S. S. Prakash, R. Veeramanikandan, Richard Kirubakaran
    Journal of Cancer Research and Clinical Oncology.2014; 140(7): 1075.     CrossRef
  • Apolipoprotein E gene ε4ε4 is associated with elevated risk of primary open angle glaucoma in Asians: a meta-analysis
    Yong Wang, Yan-Feng Zhou, Bing-Ying Zhao, Zheng-Yu Gu, Shou-Ling Li
    BMC Medical Genetics.2014;[Epub]     CrossRef
  • The potential applications of Apolipoprotein E in personalized medicine
    Sylvia Villeneuve, Diane Brisson, Natalie L. Marchant, Daniel Gaudet
    Frontiers in Aging Neuroscience.2014;[Epub]     CrossRef
  • Secretomes are a potential source of molecular targets for cancer therapies and indicate that APOE is a candidate biomarker for lung adenocarcinoma metastasis
    Zan Liu, Yuan Gao, Fengxia Hao, Xiaomin Lou, Xiuwei Zhang, Yang Li, Di Wu, Ting Xiao, Longhai Yang, Qingchang Li, Xueshan Qiu, Enhua Wang
    Molecular Biology Reports.2014; 41(11): 7507.     CrossRef
  • Age, Gender, and Cancer but Not Neurodegenerative and Cardiovascular Diseases Strongly Modulate Systemic Effect of the Apolipoprotein E4 Allele on Lifespan
    Alexander M. Kulminski, Konstantin G. Arbeev, Irina Culminskaya, Liubov Arbeeva, Svetlana V. Ukraintseva, Eric Stallard, Kaare Christensen, Nicole Schupf, Michael A. Province, Anatoli I. Yashin, Nicholas J. Schork
    PLoS Genetics.2014; 10(1): e1004141.     CrossRef
  • Apolipoprotein E Polymorphism and Colorectal Neoplasm: Results from a Meta-Analysis
    Yun Tian, Jirong Wang, Ying Ye, Liqun Sun, Yingrui Fan, Li Wang, Juan Li, Zhaoxia Wang, Keming Wang, Georgina L. Hold
    PLoS ONE.2014; 9(7): e102477.     CrossRef
  • Cognitive Impairment in Older Patients With Breast Cancer Before Systemic Therapy: Is There an Interaction Between Cancer and Comorbidity?
    Jeanne S. Mandelblatt, Robert A. Stern, Gheorghe Luta, Meghan McGuckin, Jonathan D. Clapp, Arti Hurria, Paul B. Jacobsen, Leigh Anne Faul, Claudine Isaacs, Neelima Denduluri, Brandon Gavett, Tiffany A. Traina, Patricia Johnson, Rebecca A. Silliman, R. Sco
    Journal of Clinical Oncology.2014; 32(18): 1909.     CrossRef
  • Apolipoprotein E gene polymorphism influences aggressive behavior in prostate cancer cells by deregulating cholesterol homeostasis
    GODWIN O. IFERE, RENEE DESMOND, WENDY DEMARK-WAHNEFRIED, TIM R. NAGY
    International Journal of Oncology.2013; 43(4): 1002.     CrossRef
  • Proteomic Changes Induced by Effective Chemopreventive Ratios of n-3:n-6 Fatty Acids and Tamoxifen against MNU-Induced Mammary Cancer in the Rat
    Christine G. Skibinski, Henry J. Thompson, Arunangshu Das, Andrea Manni, James D. Bortner, Anne Stanley, Bruce A. Stanley, Karam El-Bayoumy
    Cancer Prevention Research.2013; 6(9): 979.     CrossRef
  • Non-random distribution of breast cancer susceptibility loci on human chromosomes
    Khyber Saify, Mostafa Saadat
    Breast Cancer Research and Treatment.2012; 136(1): 315.     CrossRef
  • 12,512 View
  • 75 Download
  • 38 Crossref
Close layer
A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer
Jong Gwon Choi, Jae Hong Seo, Sang Cheul Oh, Chul Won Choi, Jun Suk Kim
Cancer Res Treat. 2012;44(2):127-132.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.127
AbstractAbstract PDFPubReaderePub
PURPOSE
The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer.
MATERIALS AND METHODS
Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study. Inclusion criteria included no prior systemic chemotherapy or radiation therapy, at least one radiographically documented and measurable tumor lesion, and adequate patient organ functions. The patients received 1,000 mg/m2 gemcitabine intravenously on days 1, 8 and 15, and 830 mg/m2 of oral capecitabine twice a day on days 1-21 of a 28-day cycle.
RESULTS
Fifty patients with a median age of 53 years (range, 39 to 76 years) were enrolled in the study. The median follow-up was 10.0 months. The objective response rate of the 50 patients was 48.0% (95% CI, 22.5 to 57.1%). The median time to progression and overall survival were 6.5 months (95% CI, 2.3 to 8.7 months) and 10.0 months (95% CI, 5.7 to 16.7 months), respectively. Grade 3-4 toxicities associated with chemotherapy included neutropenia (22%), anemia (8%), thrombocytopenia (6%), and hand-foot syndrome (10%).
CONCLUSION
Combination chemotherapy using gemcitabine and capecitabine was well tolerated and demonstrated promising efficacy in the treatment of advanced pancreatic cancer.

Citations

Citations to this article as recorded by  
  • Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma
    Kimmen Quan, Philip Sutera, Karen Xu, Mark E. Bernard, Steven A. Burton, Rodney E. Wegner, Herbert Zeh, Nathan Bahary, Ronald Stoller, Dwight E. Heron
    Practical Radiation Oncology.2018; 8(2): 95.     CrossRef
  • A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
    Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Ho Gak Kim, Myung Hwan Noh, Sang Hyub Lee, Yong-Tae Kim, Hyo Jung Kim, Chang Duck Kim, Dong Ki Lee, Kwang Bum Cho, Chang Min Cho, Jong Ho Moon, Dong Uk Kim, Dae Hwan Kang, Youn
    Medicine.2017; 96(1): e5702.     CrossRef
  • Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
    P. Jiménez-Fonseca, M. P. Solis, M. Garrido, L. Faez, D. Rodriguez, A. L. Ruiz, M. L. Sanchez Lorenzo, E. Uriol, M. D. Menendez, J. M. Viéitez
    Clinical and Translational Oncology.2015; 17(5): 384.     CrossRef
  • Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice
    Vincent Chee Ee Phua, Wei Quan Wong, Pei Lin Tan, Anita Zarina Bustam, Marniza Saad, Adlinda Alip, Wan Zamaniah Wan Ishak
    Asian Pacific Journal of Cancer Prevention.2015; 16(4): 1449.     CrossRef
  • An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
    Chao Tu, Feng Zheng, Jin-Yu Wang, Yuan-Yuan Li, Ke-Qing Qian
    Asian Pacific Journal of Cancer Prevention.2015; 16(14): 5681.     CrossRef
  • Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer
    Ibrahim Vedat Bayoglu, Umut Varol, Ibrahim Yildiz, Ugur Muslu, Ahmet Alacacioglu, Yuksel Kucukzeybek, Murat Akyol, Lutfiye Demir, Ahmet Dirican, Suna Cokmert, Yasar Yildiz, Bulent Karabulut, Ruchan Uslu, Mustafa Oktay Tarhan
    Asian Pacific Journal of Cancer Prevention.2014; 15(17): 7119.     CrossRef
  • Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
    Jae Yun Lim, Jang Ho Cho, Se Joon Lee, Dong Ki Lee, Dong Sup Yoon, Jae Yong Cho
    Cancer Research and Treatment.2014; 47(2): 266.     CrossRef
  • Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
    Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody
    PLoS ONE.2014; 9(8): e104346.     CrossRef
  • Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance
    Chunfang Xu, Airong Wu, Hua Zhu, Huaying Fang, Lele Xu, Jianxin Ye, Jiaqing Shen
    Biomedicine & Pharmacotherapy.2013; 67(2): 133.     CrossRef
  • 11,812 View
  • 64 Download
  • 9 Crossref
Close layer
Irradiation of Donor Mononuclear Cells for Treatment of Chemorefractory Metastatic Solid Cancers: A Community-Based Immune Transplant Pilot Study
John T. Reynolds, John M. Watkins, Tarek A. Dufan, Shrikant S. Kubsad
Cancer Res Treat. 2012;44(2):133-141.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.133
AbstractAbstract PDFPubReaderePub
PURPOSE
Chemotherapy has demonstrated ability to generate tumor antigens secondary to induction of apoptosis, against which human leukocyte antigen-compatible, irradiated, related donor mononuclear cells may be administered with immune stimulation to activate antigen presenting and cytotoxic T cells, while minimizing risk of graft-versus-host disease (GVHD). The present study endeavours to describe feasibility and efficacy of this treatment, specifically in the community setting.
MATERIALS AND METHODS
Eligible patients had rapidly progressive, chemorefractory metastatic solid tumors. Treatment consisted of intravenous etoposide and cyclosporine for three days followed by granulocyte-macrophage colony-stimulating factor for 5 days. The following week, 5x10(7) haploidentical or more closely matched irradiated donor mononuclear cells were given weekly for 10 weeks along with interleukin-2.
RESULTS
Three patients were enrolled, and the regimen was well-tolerated, with no GVHD observed. All patients had clinical response, despite advanced and heavily pretreated disease.
CONCLUSION
The above-outlined protocol demonstrates favorable tolerability and efficacy, and appears to be feasible in the community setting. While the optimal chemotherapy, immunostimulation, and irradiation regimens may be further optimized, future investigation appears warranted, and may include community oncology programs.

Citations

Citations to this article as recorded by  
  • Feasibility and Pilot Studies in Palliative Care Research: A Systematic Review
    Terry A. Jones, Timothy S. Olds, David C. Currow, Marie T. Williams
    Journal of Pain and Symptom Management.2017; 54(1): 139.     CrossRef
  • Irradiation of peripheral blood mononuclear cells with 7.5 Gy X-rays prior to donor lymphocyte infusion inhibits proliferation while preserving cytotoxicity, and improves the effectiveness of HSCT in patients with hematological malignancies
    Yong-Qiu Wei, Xi-Nan Cen, Hui-Hui Liu, Yu-Hua Sun, Yong-Jin Shi, Wei Liu, Yu-Jun Dong, Han-Yun Ren
    Oncology Letters.2017; 13(6): 4101.     CrossRef
  • 11,089 View
  • 57 Download
  • 2 Crossref
Close layer
Case Reports
Metastatic Skin Lesions on Lower Extremities in a Patient with Recurrent Serous Papillary Ovarian Carcinoma: A Case Report and Literature Review
Moon-Kyung Kim, Seo-Hee Kim, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Jeoung-Won Lee, Je-Ho Lee, Duk-Soo Bae, Byoung-Gie Kim
Cancer Res Treat. 2012;44(2):142-145.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.142
AbstractAbstract PDFPubReaderePub
Clinical observation of skin metastasis in ovarian cancer cases is relatively uncommon. And distant metastatic skin lesions including the extremities are much rarer still as most metastatic skin lesions are located in the skin in the abdominal wall adjacent to where the primary ovarian tumors exist. We report the case of a 60-year-old woman who presented skin lesions on both lower extremities as a consequence of the metastasis of serous papillary adenocarcinoma of the ovary. She presented with erythematous and painful cutaneous nodules on both upper legs and in the inguinal area 42 months after initial diagnosis of ovarian cancer. Skin biopsy revealed metastasis of adenocarcinoma in the dermis. She was treated with surgical excision and systemic chemotherapy. Literature review has suggested that a combined modality approach including surgical excision and chemotherapy may be useful in the management of skin metastases due to ovarian cancer.

Citations

Citations to this article as recorded by  
  • Cutaneous Metastases—Histological Particularities of Multifaceted Entities
    Andreea Cătălina Tinca, Bianca Andreea Lazar, Andreea Raluca Cozac-Szőke, Georgian Nicolae Radu, Simina Petra Simion, Diana Maria Chiorean, Irina Bianca Kosovski, Adrian Horațiu Sabău, Raluca Niculescu, Iuliu Gabriel Cocuz, Raluca-Diana Hagău, Emoke Andre
    Dermatopathology.2025; 12(2): 14.     CrossRef
  • Skin metastasis from ovarian cancer with somatic BRCA1 mutation: A case report and literature review
    Jingheng Zhang, Wenfeng He, Zhenhua Zhang, Hui Dong, Xiangyu Deng, Qinglian Wen, Dan Li
    Oncology Letters.2024;[Epub]     CrossRef
  • Metastasis of ovarian cancer to nasal skin and skin on the trunk: a rare case report
    Chen Chen, Ouyang Yingyao, Xiang Yan, He Qianru, Wang Hong, Chen Chen, Yang Lei
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • A Rare and Sinister Presentation of Cutaneous Metastasis over Right Lower Limb in a Case of Ovarian Carcinoma
    Preema Sinha, Parul Kamboj, Anamika Sinha, Juhi Sharma
    Journal of Marine Medical Society.2022; 24(2): 211.     CrossRef
  • Clinicopathologic features of cutaneous metastases from internal malignancies
    Hyeong Mok Kwon, Gyu Yeong Kim, Dong Hoon Shin, Young Kyung Bae
    Journal of Pathology and Translational Medicine.2021; 55(4): 289.     CrossRef
  • Rare Sites Metastasis in Ovarian Carcinoma: a Compilation of 3 Case Reports
    Megha Nandwani, Debabrata Barmon, Dimpy Begum, Amal C. Kataki
    Indian Journal of Surgical Oncology.2020; 11(1): 150.     CrossRef
  • Cutaneous metastasis of PD-L1 positive ovarian carcinoma
    Victoria Hastings, Jennifer McEachron, Marguax J. Kanis
    Gynecologic Oncology Reports.2020; 33: 100607.     CrossRef
  • PET/CT for Evaluation of Ovarian Cancer
    Jukka Kemppainen, Johanna Hynninen, Johanna Virtanen, Marko Seppänen
    Seminars in Nuclear Medicine.2019; 49(6): 484.     CrossRef
  • Cutaneous Metastases in Ovarian Cancer
    Isao Otsuka
    Cancers.2019; 11(9): 1292.     CrossRef
  • Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature
    Gina Nam, Young-mee Lim, Min Sun Cho, Junghye Lee, Yun Hwan Kim
    Obstetrics & Gynecology Science.2017; 60(6): 593.     CrossRef
  • Two independent incidences of skin metastases in the umbilicus and abdominal wall in ovarian serous adenocarcinoma
    Hongyan Cheng, Chunmei Gao, Runtong Zhang, Zhaojie Yang, Guiyu Zhang
    Medicine.2017; 96(49): e9118.     CrossRef
  • Cutaneous metastases from adenocarcinoma of the ovary
    Heidi H. McDonald, Milton R. Moore, Jeffrey J. Meffert
    JAAD Case Reports.2016; 2(5): 406.     CrossRef
  • Ovarian carcinoma presenting as cutaneous nasal metastasis
    Ana Marta António, João Vitor Alves, João Goulão, Elvira Bártolo
    Anais Brasileiros de Dermatologia.2016; 91(5 suppl 1): 101.     CrossRef
  • 12,398 View
  • 72 Download
  • 13 Crossref
Close layer
A Case of Erdheim-Chester Disease with Asymptomatic Renal Involvement
Hyun Jung Lee, Kyoung Yul Lee, Dong-Yeop Shin, Yun Gyoo Lee, Se Youn Choi, Kyung Chul Moon, Il-Kyu Han, Tae Min Kim
Cancer Res Treat. 2012;44(2):146-150.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.146
AbstractAbstract PDFPubReaderePub
Erdheim-Chester disease is a rare non-Langerhans-cell histiocytosis involving bones and multiple organs. Its clinical course can vary, from an asymptomatic state to a fatal disease, with renal involvement being a common cause of death. A 41-year-old man presented with a 10-month history of bilateral lower limb pain. Left perirenal soft-tissue infiltration had been found incidentally two years earlier. No progression of the lesion or deterioration of renal function was observed for a period of two years. At admission, plain radiography and magnetic resonance imaging of the patient's lower limbs showed patchy osteosclerosis. Biopsy of the tibia revealed histiocytic infiltration, which was found to be positive for CD68 and negative for CD1a. This report describes an unusual case of Erdheim-Chester disease involving a stationary course of disease with no specific treatment for a long period of time.

Citations

Citations to this article as recorded by  
  • Radiological assessment of extremity bone involvement in Erdheim-Chester disease: a systematic review of case reports
    Arash Azhideh, Alireza Pouramini, Sara Haseli, Elahe Abbaspour, Gita Karande, Fatemeh Kafi, Majid Chalian
    Skeletal Radiology.2024;[Epub]     CrossRef
  • Erdheim–Chester Disease Involving the Biliary System and Mimicking Immunoglobulin G4-Related Disease: A Case Report
    Hyuk Gi Hong, Yong Eun Chung, June Park, Yeo Eun Kim
    Journal of the Korean Society of Radiology.2023; 84(3): 757.     CrossRef
  • The role of nuclear medicine in the diagnosis of Erdheim–chester disease. A series of clinical observations
    A. S. Krylov, A. D. Ryzhkov, A. A. Odzharova, Ya. A. Shchipakhina, E. E. Stanyakina, A. A. Martinovich, K. D. Ilkaev, A. M. Stroganova, S. L. Dranko, O. P. Bliznyukovv, A. V. Kuzin, P. A. Zeynalova, A. A. Semenova, M. B. Dolgushin
    Oncohematology.2020; 15(1): 28.     CrossRef
  • Erdheim–Chester disease. Literature review and clinical case
    A. S. Krylov, M. B. Dolgushin, A. D. Ryzhkov, A. A. Odzharova, Ya. A. Shchipakhina, E. A. Sushentsov, O. P. Bliznyukov, S. M. Kaspshik, A. A. Martinovich, A. M. Stroganova, S. L. Dranko, P. A. Zeynalova, T. T. Valiev
    Oncohematology.2020; 15(2): 61.     CrossRef
  • Magnetic Resonance Imaging of Perirenal Pathology
    James F. Glockner, Christine U. Lee
    Canadian Association of Radiologists Journal.2016; 67(2): 149.     CrossRef
  • Erdheim-Chester Disease with Perirenal Masses Containing Macroscopic Fat Tissue
    Jonghyun Byeon, Kyung Ah Kim, Seong Su Hwang, Soo Youn Park, Hyun A Kim
    Journal of the Korean Society of Radiology.2015; 72(2): 143.     CrossRef
  • Urologic Manifestations of Erdheim-Chester Disease
    Daniel A. Yelfimov, Deborah J. Lightner, Matthew K. Tollefson
    Urology.2014; 84(1): 218.     CrossRef
  • Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series
    Roei D Mazor, Mirra Manevich-Mazor, Anat Kesler, Orna Aizenstein, Iris Eshed, Ronald Jaffe, Yakov Pessach, Ilan Goldberg, Eli Sprecher, Iris Yaish, Alexander Gural, Chezi Ganzel, Yehuda Shoenfeld
    BMC Medicine.2014;[Epub]     CrossRef
  • A Rare Cause of Late-Onset Cerebellar Ataxia: Erdheim–Chester Disease
    Senthilkumar V. Shanmugam, Madhan Kolappan, Mamta Garg, Winston J. Rennie, Peter Furness, Yusuf A. Rajabally
    The Cerebellum.2013; 12(4): 593.     CrossRef
  • Reply to Commentary on "A Case of Erdheim-Chester Disease with Asymptomatic Renal Involvement"
    Hyun Jung Lee, Tae Min Kim
    Cancer Research and Treatment.2012; 44(4): 280.     CrossRef
  • Commentary on "A Case of Erdheim-Chester Disease with Asymptomatic Renal Involvement"
    Gioacchino Li Cavoli
    Cancer Research and Treatment.2012; 44(4): 279.     CrossRef
  • 15,778 View
  • 78 Download
  • 11 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP